131,796 Shares in KalVista Pharmaceuticals, Inc. $KALV Acquired by NEXTBio Capital Management LP

NEXTBio Capital Management LP acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 131,796 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,129,000. KalVista Pharmaceuticals comprises about 1.2% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 22nd largest holding.

Other hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in KalVista Pharmaceuticals in the 3rd quarter worth approximately $55,000. Tower Research Capital LLC TRC raised its holdings in KalVista Pharmaceuticals by 816.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after acquiring an additional 7,180 shares during the last quarter. Cerro Pacific Wealth Advisors LLC purchased a new position in KalVista Pharmaceuticals in the 4th quarter worth approximately $162,000. Finally, Diversified Trust Co. purchased a new position in KalVista Pharmaceuticals in the 4th quarter worth approximately $176,000.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CFO Brian Piekos sold 1,489 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $39,875.42. Following the completion of the sale, the chief financial officer owned 21,661 shares of the company’s stock, valued at $580,081.58. The trade was a 6.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicole Sweeny sold 1,489 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total transaction of $39,875.42. Following the sale, the insider directly owned 59,291 shares of the company’s stock, valued at approximately $1,587,812.98. The trade was a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 254,602 shares of company stock worth $4,656,670. 4.30% of the stock is currently owned by insiders.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $27.00 on Friday. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12 month low of $9.83 and a 12 month high of $27.00. The company has a market cap of $1.44 billion, a PE ratio of -7.80 and a beta of -0.12. The company has a 50 day simple moving average of $24.16 and a two-hundred day simple moving average of $18.79.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to analyst estimates of $39.03 million. Research analysts forecast that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on KALV shares. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. HC Wainwright downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $37.00 to $27.00 in a research report on Friday, May 1st. Stifel Nicolaus lifted their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Citizens Jmp downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.